food-technology-biotechnology-2018-posters

Page 53

allied

academies

Journal of Biotechnology and Phytochemistry| Volume: 2

October 25-26, 2018 | Frankfurt, Germany

Joint Event

Biotechnology & Medical Microbiology

World Congress on

International Conference on

Food Science & Technology

APC-100, a novel pharmaceutical neuroregeneration therapy for the Alzheimer’s disease

Kiminobu Sugaya

University of Central Florida, USA

ne of the primary hurdles of Alzheimer’s disease (AD)

therapy is that it requires more then one solution to

successfully stop or reverse it since the disease degenerate

many different types of cells as compare to the other

neurodegenerative diseases. That is why the stem cells could

be useful to treat AD since they could produce those different

types of cells according to the environments. However, to use

stem cells, influences from the pathological environment of

AD must be addressed. The AD brain over produces amyloid

precursor protein (APP), which then results in amyloid plaques,

one of the hallmarks of AD. We found that the pathological

level of APP prevents neural stem cells (NSCs) to differentiate

into neurons. Our approach is to combine small molecule

therapeutics for both modifying the pathological condition

AD and increasing endogenous NSCs. With phenserine, a drug

reduces APP production, we were able to control the APP to a

normal level, which allows NSCs to differentiate into neurons.

Then we combined KS-217, a pyro pyrimidine derivative, which

pass through the blood brain barrier to increase endogenous

NSCs at the significant level, eliminating the need of NSCs

transplantation. This combination therapeutic approach

(APC-100) has proven effective in improving cognition and

increasing neuroregeneration in AD mice model. APC-100

will introduce totally new concept to AD stem cell therapy,

which does not require any transplantable cell materials.